Why Roche Holding Stock Popped Today
Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib drug for treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Image source: Getty Images.
Conducted over more than 96 weeks, the first trial "significantly reduced the annualized relapse rate (ARR) compared to teriflunomide," an RMS drug developed by Sanofi and currently available as a generic from multiple manufacturers.
Source Fool.com
Roche Holding AG ADR Stock
€41.41
-1.550%
With 3 Buy predictions and 2 Sell predictions the community is currently undecided on Roche Holding AG ADR.
As a result the target price of 45 € shows a slightly positive potential of 8.68% compared to the current price of 41.41 € for Roche Holding AG ADR.
